Skip to main content
main-content

03.01.2019 | Thoracic Oncology | Ausgabe 3/2019

Annals of Surgical Oncology 3/2019

Baseline and Postoperative C-reactive Protein Levels Predict Long-Term Survival After Lung Metastasectomy

Zeitschrift:
Annals of Surgical Oncology > Ausgabe 3/2019
Autoren:
MD Ugo Pastorino, MD Daniele Morelli, MD Giovanni Leuzzi, MD Luigi Rolli, BS Paola Suatoni, PhD Francesca Taverna, BL Elena Bertocchi, PhD Mattia Boeri, PhD Gabriella Sozzi, PhD Anna Cantarutti, PhD Giovanni Corrao, MD Alessandro Gronchi
Wichtige Hinweise

Electronic supplementary material

The online version of this article (https://​doi.​org/​10.​1245/​s10434-018-07116-7) contains supplementary material, which is available to authorized users.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Abstract

Background

Blood level of C-reactive protein (CRP) at diagnosis is a well-know prognostic bio-marker in different primary tumors, but its role has not been investigated in resectable lung metastases. The aim of our study is to assess the predictive value of baseline (CRP0) and 3rd postoperative day (CRP3) levels on long-term survival of patients undergoing lung metastasectomy.

Methods

A total of 846 consecutive patients underwent the first pulmonary resection for lung metastases between January 2003 and December 2015, including 611 (72%) single surgical procedures, 235 (28%) multiple metastasectomies, 501 (59%) epithelial primary tumors, 276 (33%) sarcomas, 66 (8%) melanomas, 286 (33.8%) with 0 risk factors (CRP0 ≤ 2 and CRP3 ≤ 84 mg/L) and 560 (66.2%) with ≥ 1 risk factor (CRP0 > 2 and/or CRP3 > 84 mg/L).

Results

Cumulative 5-year survival was 57% in patients with low CRP (0 risk factors) versus 43% in high CRP (≥ 1 risk factor, p < 0.0002), 62% versus 50% respectively for epithelial tumors (p < 0.0140), and 51% versus 34% for sarcomas (p < 0.0111). Multivariable Cox analysis confirmed a mortality hazard ratio of 2.5 at 1-year and 1.5 at 5-years in patients with high CRP.

Conclusions

Baseline and postoperative CRP levels predict survival of patients with resectable lung metastases. These data provide a rationale for prospective clinical trials testing the efficacy of anti-inflammatory or immune-modulating agents as “adjuvant” therapy after lung metastasectomy, in patients with elevated pre- and/or postoperative CRP levels.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Weitere Produktempfehlungen anzeigen
Zusatzmaterial
Fig. 1 Kaplan–Meier survival curves by number of metastasectomy (A. single, B. multiple), according to C-reactive protein measured at baseline (CRP0) and 3 days after surgery (CRP3). Low CRP: CRP0 ≤ 2 and CRP3 ≤ 84-high CRP: CRP0 > 2 or CRP3 > 84 (TIFF 974 kb)
10434_2018_7116_MOESM1_ESM.tif
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 3/2019

Annals of Surgical Oncology 3/2019 Zur Ausgabe
  1. Sie können e.Med Chirurgie 14 Tage kostenlos testen (keine Print-Zeitschrift enthalten). Der Test läuft automatisch und formlos aus. Es kann nur einmal getestet werden.

  2. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

Neu im Fachgebiet Chirurgie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Chirurgie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise